Palbinas 125(Palbociclib 125mg)

Palbinas 125, also referred to as Palbociclib 125mg, is a kinase inhibitor employed for treating advanced or metastatic breast cancer in women having hormone receptor-positive and HER2-negative tumors. It is prescribed along with either an aromatase inhibitor or fulvestrant, based on the patient's medical history, to determine the appropriate endocrine therapy.

DOSAGE AND ADMINISTRATION

The recommended way to start the treatment is by taking a 125mg oral dose with food every day for 21 days, followed by a 7-day break without treatment. Depending on the person's ability to tolerate the medication and any safety concerns, adjustments to the dosage may be necessary.

Cost of palbociclib:

Palbociclib costs only 6% of its price in the United States when purchased in India. The generic form of Palbociclib is a prescribed medication that contains the same active ingredient and follows the same pharmaceutical regulations as the branded version.

Palbinas 125(Palbociclib 125mg ) Side Effects：

The use of Palbociclib may result in several common side effects, including fatigue, hair thinning or loss, mouth sores, nausea, vomiting, diarrhea, rash, loss of appetite, abnormal liver blood tests, low red blood cell counts, low platelet counts, and low white blood cell counts. Frequent monitoring of blood cell counts is essential, as low white blood cell counts can lead to severe infections. In case of necessity, healthcare providers may need to interrupt treatment, lower the dosage, or delay the start of a new cycle. Additionally, Palbociclib may affect male fertility.

For additional prescribing information, please refer to the "FDA Prescribing Information."